1. Scrip
  2. >>COVID-19

Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection

 
• By Scrip Team

The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.

COVID-19 vaccine
Pfizer/BioNTech announced six-month and variant data for BNT162b2, while J&J said it anticipates meeting its supply goals • Source: Shutterstock

Pfizer Inc. and BioNTech SE continue to roll out additional data supporting their mRNA vaccine against SARS-CoV-2 with updated data from the Phase III study of BNT162b2 showing similar levels of protection up to six months later among people who received both doses. The updated data also provide more evidence of efficacy against the B.1.351 South African variant strain.

The findings of the latest analysis bolsters recent data showing BNT162b2’s efficacy and an early advantage over competitors, although similar data is expected soon for the other COVID-19 vaccines. For...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By Jung Won Shin

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.